Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;33(4):823-5.
doi: 10.2337/dc09-1834. Epub 2010 Jan 26.

Changes in glitazone use among office-based physicians in the U.S., 2003-2009

Affiliations

Changes in glitazone use among office-based physicians in the U.S., 2003-2009

Andrew Cohen et al. Diabetes Care. 2010 Apr.

Abstract

Objective: Little is known regarding recent changes in glitazone use.

Research design and methods: Interrupted time series analyses of nationally representative office-visit data using IMS Health's National Disease and Therapeutic Index.

Results: From 2003 through 2005, glitazone use increased steadily. From February 2005 to January 2007, rosiglitazone use decreased by 16% (95% CI -20 to -11) annually; pioglitazone use increased at an annual rate of 14% (9-18). During a period of Food and Drug Administration (FDA) advisories, rosiglitazone use declined sharply from 0.42 million monthly treatment visits (February 2007) to 0.13 million monthly visits (May 2008). Pioglitazone use remained stable, accounting for approximately 5.8 million physician visits (77% of all glitazone use) where a treatment was used during the final 12 months of observation.

Conclusions: The combined effect of scientific publications, advisories, and media exposure was associated with a substantial decrease in rosiglitazone use. Despite a class-level FDA advisory, pioglitazone use was not similarly affected.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trends in monthly glitazone use among office-based physicians in the U.S., 1999–2009.

References

    1. Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National trends in treatment of type 2 diabetes mellitus, 1994–2007. Arch Intern Med 2008;168:2088–2094 - PMC - PubMed
    1. Wooltorton E. Rosiglitazone (avandia) and pioglitazone (actos) and heart failure. CMAJ 2002;166:219 - PMC - PubMed
    1. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457–2471 - PubMed
    1. Federal Drug Administration, Center for Drug Evaluation and Research. Label and approval history [Internet]. Available at http://www.accessdata.fda.gov/Scripts/cder/drugsatfda/index.cfm?fuseacti.... Accessed 1 July 2009
    1. Walton SM, Schumock GT, Lee KV, Alexander GC, Meltzer D, Stafford RS. Prioritizing medications for policy and research initiatives examining off-label prescribing. Pharmacotherapy 2008;28:1443–1452 - PMC - PubMed

Publication types

MeSH terms